Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 15/20 | 0.62 |
| ▸ | PPARD | Q03181 | 5/20 | 0.60 |
| ▸ | PPARG | P37231 | 4/20 | 0.60 |
| ▸ | PPARA | Q07869 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | GRM5 | P41594 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4208749 | 0.91 | MAOB (0.53) | FFAR1PPARDPPARGMAOBMAOA | |
| SCHEMBL14207883 | 0.90 | FFAR1 (0.62) | FFAR1PPARDPPARGMAOB | |
| SCHEMBL4206530 | 0.88 | FFAR1 (0.52) | FFAR1PPARDPPARGMAOBMAOA | |
| SCHEMBL4211545 | 0.88 | FFAR1 (0.50) | FFAR1PPARDPPARGMAOBMAOA | |
| SCHEMBL12214587 | 0.87 | FFAR1 (0.54) | FFAR1PPARDMAOBMAOANPC1 | |
| SCHEMBL1846829 | 0.83 | MAOB (0.58) | FFAR1MAOBMAOANPC1ALDH1A1 | |
| SCHEMBL13264375 | 0.82 | PPARD (0.64) | FFAR1PPARDPPARGPPARA | |
| SCHEMBL4219623 | 0.82 | MAOB (0.56) | FFAR1MAOBMAOANPC1ALDH1A1 | |
| SCHEMBL27704540 | 0.82 | MAOB (0.51) | FFAR1PPARDPPARGMAOBMAOA | |
| SCHEMBL15687712 | 0.82 | FFAR1 (0.50) | FFAR1PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079467-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2015-11-18 | — | — | EP | disclosed |
| US-8039484-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039484-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2011-10-18 | — | — | US | disclosed |
| US-7759493-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759493-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2010-07-20 | — | — | US | disclosed |
| US-20100105725-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2010-04-29 | — | — | US | disclosed |
| US-20100105725-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2010-04-29 | — | — | US | disclosed |
| US-20090312303-A1 | Antidiabetic Bicyclic Compounds | MERCK & CO., INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312303-A1 | Antidiabetic Bicyclic Compounds | MERCK & CO., INC. (US) | 2009-12-17 | — | — | US | disclosed |
| EP-1846379-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK & CO INC (US) | 2009-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105725-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | GPR119, FFAR2, GPR65 | FFAR1 8/4885PPARD 19/4885PPARG 7/4885 |
| US-20090312303-A1 | Antidiabetic Bicyclic Compounds | GPR119, GPR55, GPR65 | FFAR1 12/4885PPARD 15/4885PPARG 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.